Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abametapir - Hatchtech

Drug Profile

Abametapir - Hatchtech

Alternative Names: BRN-0123183; DeOvo Lotion; DFD-11; HA-44; Ha44; Ha44 Gel; Xeglyze Lotion

Latest Information Update: 28 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hatchtech
  • Developer Dr Reddys Laboratories; Hatchtech
  • Class Antiparasitics; Heterocyclic compounds; Pyridines; Small molecules
  • Mechanism of Action Chelating agents; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Pediculosis

Most Recent Events

  • 31 Mar 2019 Abametapir is still in preregistration phase for Pediculosis in USA
  • 14 Sep 2015 Hatchteck enters into a deal with Dr Reddys Laboratories for commercialisation of abametapir in USA, Canada, India, Australia, New Zealand, Venezuala and countries of Common Independent States
  • 27 Jul 2015 No recent reports on development identified - Phase-II for Pediculosis (In adolescents, In children, In adults) in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top